Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | (460,021) | (193,076) | (31,573) | (119,531) | (105,906) | |
| Invested capital2 | (117,411) | 91,721) | (87,987) | (106,877) | (78,273) | |
| Performance Ratio | ||||||
| ROIC3 | — | -210.50% | — | — | — | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | 14.05% | 12.89% | — | — | — | |
| Amgen Inc. | 16.11% | 15.93% | — | — | — | |
| Bristol-Myers Squibb Co. | 6.37% | 8.29% | — | — | — | |
| Danaher Corp. | 8.76% | 9.01% | — | — | — | |
| Eli Lilly & Co. | 17.98% | 19.39% | — | — | — | |
| Gilead Sciences Inc. | 8.09% | 14.43% | — | — | — | |
| Johnson & Johnson | 14.16% | 19.23% | — | — | — | |
| Merck & Co. Inc. | 19.14% | 18.87% | — | — | — | |
| Pfizer Inc. | 28.01% | 20.98% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 28.87% | 72.50% | — | — | — | |
| Thermo Fisher Scientific Inc. | 7.76% | 9.42% | — | — | — | |
| Vertex Pharmaceuticals Inc. | 22.66% | 23.86% | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2022 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × -460,021 ÷ -117,411 = —
4 Click competitor name to see calculations.
The financial trajectory from 2018 to 2022 is characterized by persistent operational losses and significant volatility in the capital structure. The widening gap between operating costs and revenue is evident in the accelerating deficit of net operating profit, while the inconsistent nature of invested capital complicates the assessment of capital efficiency.
- Net Operating Profit After Taxes (NOPAT)
- NOPAT remained negative across the entire period, indicating that the entity did not generate positive operating income. While there was a notable reduction in losses in 2020, where NOPAT improved to -31.57 million, this trend reversed sharply thereafter. By 2022, NOPAT declined to -460.02 million, representing a substantial increase in operational deficits compared to the 2018 starting point of -105.91 million.
- Invested Capital
- Invested capital demonstrated extreme fluctuations and remained negative for the majority of the period. Values were negative from 2018 through 2020, shifted to a positive 91.72 million in 2021, and returned to a negative -117.41 million in 2022. This pattern suggests a highly unstable capital base or a financing structure where current liabilities frequently exceed the sum of long-term debt and equity.
- Return on Invested Capital (ROIC)
- A calculable ROIC is only present for the 2021 fiscal year, yielding a result of -210.50%. This negative return reflects the impact of operating losses against a positive capital base. For the remaining years, the occurrence of negative invested capital renders the ROIC ratio mathematically indeterminate or financially meaningless, preventing a consistent year-over-year trend analysis of capital productivity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Decomposition of ROIC
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The analysis of return on invested capital components reveals a period of severe operational instability and deepening losses, characterized by extreme volatility in profitability metrics.
- Operating Profit Margin (OPM)
- The operating profit margin remained consistently negative from 2018 to 2022. A downward trend was initially observed as the margin moved from -335.88% in 2018 to -442.74% in 2019. A significant, though temporary, recovery occurred in 2020, with the margin improving to -20.48%. This was followed by a sharp deterioration to -265.75% in 2021 and an extreme collapse to -6,006.66% in 2022, indicating a substantial increase in operating losses relative to revenue generation.
- Return on Invested Capital (ROIC) Decomposition
- In 2021, the ROIC was -210.50%. This figure is derived from the interaction between a negative operating profit margin of -265.75% and a capital turnover ratio of 0.77. The negative profitability component is the primary driver of the ROIC, resulting in a significant erosion of invested capital during that period.
- Effective Cash Tax Rate (CTR)
- The metric for 1 minus the effective cash tax rate remained stagnant at 100.00% across the entire five-year period. This indicates a zero effective cash tax rate, which is consistent with a company experiencing continuous operating losses and utilizing tax shields or lacking taxable income.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Profit Margin (OPM)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | (460,021) | (193,076) | (31,573) | (119,531) | (105,906) | |
| Add: Cash operating taxes2 | 4,236) | 5,911) | 2,317) | 575) | 102) | |
| Net operating profit before taxes (NOPBT) | (455,785) | (187,165) | (29,256) | (118,956) | (105,805) | |
| Revenues | 94,588) | 70,428) | 55,828) | 26,868) | 31,501) | |
| Add: Increase (decrease) in deferred revenue | (87,000) | —) | 87,000) | —) | —) | |
| Adjusted revenues | 7,588) | 70,428) | 142,828) | 26,868) | 31,501) | |
| Profitability Ratio | ||||||
| OPM3 | -6,006.66% | -265.75% | -20.48% | -442.74% | -335.88% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | 26.77% | 27.06% | — | — | — | |
| Amgen Inc. | 35.35% | 32.55% | — | — | — | |
| Bristol-Myers Squibb Co. | 19.38% | 20.31% | — | — | — | |
| Danaher Corp. | 27.12% | 27.65% | — | — | — | |
| Eli Lilly & Co. | 25.19% | 23.01% | — | — | — | |
| Gilead Sciences Inc. | 24.71% | 34.43% | — | — | — | |
| Johnson & Johnson | 22.67% | 24.39% | — | — | — | |
| Merck & Co. Inc. | 30.22% | 30.60% | — | — | — | |
| Pfizer Inc. | 38.53% | 29.86% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 39.28% | 57.80% | — | — | — | |
| Thermo Fisher Scientific Inc. | 18.33% | 23.92% | — | — | — | |
| Vertex Pharmaceuticals Inc. | 46.55% | 36.91% | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
OPM = 100 × NOPBT ÷ Adjusted revenues
= 100 × -455,785 ÷ 7,588 = -6,006.66%
4 Click competitor name to see calculations.
The operating performance from 2018 to 2022 is characterized by consistent net operating losses and extreme volatility in revenue and profit margins. The company has not achieved operating profitability during this period, with losses expanding significantly toward the end of the timeframe.
- Net Operating Profit Before Taxes (NOPBT)
- Operating losses remained persistent throughout the five-year period. A temporary reduction in losses occurred in 2020, where NOPBT improved to -29.25 million USD. However, this was followed by a sharp deterioration in 2021 and 2022, with losses escalating to -187.16 million USD and -455.78 million USD, respectively. This indicates a substantial increase in operating expenditures that far outpaced revenue generation in the latter years.
- Adjusted Revenues
- Revenue streams exhibited high instability. After remaining relatively flat between 2018 and 2019, revenues peaked in 2020 at 142.83 million USD. This peak was followed by a steady decline, falling to 70.43 million USD in 2021 and collapsing to 7.59 million USD by December 31, 2022. This downward trajectory suggests a significant loss of income-generating capacity or the conclusion of specific revenue-producing milestones.
- Operating Profit Margin (OPM)
- The operating profit margin reflects the combined impact of rising losses and falling revenues. The margin reached its most favorable point in 2020 at -20.48%, coinciding with the peak in adjusted revenues. Following this, the margin deteriorated rapidly. By 2022, the OPM reached -6,006.66%, a result of the simultaneous occurrence of the highest recorded operating loss and the lowest recorded revenue in the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Turnover of Capital (TO)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 94,588) | 70,428) | 55,828) | 26,868) | 31,501) | |
| Add: Increase (decrease) in deferred revenue | (87,000) | —) | 87,000) | —) | —) | |
| Adjusted revenues | 7,588) | 70,428) | 142,828) | 26,868) | 31,501) | |
| Invested capital1 | (117,411) | 91,721) | (87,987) | (106,877) | (78,273) | |
| Efficiency Ratio | ||||||
| TO2 | — | 0.77 | — | — | — | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | 0.71 | 0.59 | — | — | — | |
| Amgen Inc. | 0.62 | 0.60 | — | — | — | |
| Bristol-Myers Squibb Co. | 0.64 | 0.58 | — | — | — | |
| Danaher Corp. | 0.40 | 0.40 | — | — | — | |
| Eli Lilly & Co. | 1.18 | 1.08 | — | — | — | |
| Gilead Sciences Inc. | 0.59 | 0.57 | — | — | — | |
| Johnson & Johnson | 0.83 | 0.96 | — | — | — | |
| Merck & Co. Inc. | 0.80 | 0.69 | — | — | — | |
| Pfizer Inc. | 0.91 | 0.94 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.99 | 1.48 | — | — | — | |
| Thermo Fisher Scientific Inc. | 0.54 | 0.49 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 0.68 | 0.81 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Invested capital. See details »
2 2022 Calculation
TO = Adjusted revenues ÷ Invested capital
= 7,588 ÷ -117,411 = —
3 Click competitor name to see calculations.
The financial performance between 2018 and 2022 is characterized by significant volatility in both revenue generation and the capital structure. A lack of consistency in invested capital prevents a continuous longitudinal analysis of capital efficiency, as traditional turnover metrics are only applicable during periods of positive invested capital.
- Adjusted Revenue Trends
- Revenues exhibited extreme fluctuations throughout the period. After remaining relatively stable between 2018 and 2019, a substantial surge occurred in 2020, reaching a peak of 142.8 million US dollars. This was followed by a sharp decline in 2021 to 70.4 million US dollars and a further collapse to 7.6 million US dollars by the end of 2022. This pattern suggests an erratic revenue stream, potentially linked to non-recurring milestone payments or shifting contractual arrangements.
- Invested Capital Stability
- The invested capital base remained predominantly negative throughout the analyzed timeframe, appearing negative in 2018, 2019, 2020, and 2022. The only instance of positive invested capital occurred in 2021, totaling 91.7 million US dollars. The prevalence of negative invested capital indicates a financial structure where liabilities or other accounting adjustments offset the asset base, rendering standard return and turnover calculations mathematically atypical for most of the period.
- Turnover of Capital (TO) Analysis
- A turnover ratio is only recorded for the 2021 fiscal year, standing at 0.77. This indicates that for every dollar of invested capital, the entity generated approximately 0.77 dollars in adjusted revenue. The absence of turnover figures for the remaining years is a direct consequence of the negative invested capital values, which precludes the calculation of a meaningful positive turnover ratio.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Effective Cash Tax Rate (CTR)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | (460,021) | (193,076) | (31,573) | (119,531) | (105,906) | |
| Add: Cash operating taxes2 | 4,236) | 5,911) | 2,317) | 575) | 102) | |
| Net operating profit before taxes (NOPBT) | (455,785) | (187,165) | (29,256) | (118,956) | (105,805) | |
| Tax Rate | ||||||
| CTR3 | — | — | — | — | — | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | 25.72% | 18.70% | — | — | — | |
| Amgen Inc. | 27.01% | 18.93% | — | — | — | |
| Bristol-Myers Squibb Co. | 48.91% | 29.34% | — | — | — | |
| Danaher Corp. | 19.69% | 18.58% | — | — | — | |
| Eli Lilly & Co. | 39.25% | 22.28% | — | — | — | |
| Gilead Sciences Inc. | 44.70% | 25.84% | — | — | — | |
| Johnson & Johnson | 25.14% | 17.53% | — | — | — | |
| Merck & Co. Inc. | 20.99% | 10.42% | — | — | — | |
| Pfizer Inc. | 20.44% | 25.02% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 26.00% | 15.19% | — | — | — | |
| Thermo Fisher Scientific Inc. | 21.94% | 19.89% | — | — | — | |
| Vertex Pharmaceuticals Inc. | 28.16% | 19.91% | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 4,236 ÷ -455,785 = —
4 Click competitor name to see calculations.
Analysis reveals a persistent disconnect between operating profitability and cash tax obligations over the five-year period ending December 31, 2022. While operating profits remained negative throughout the duration, cash tax payments were consistently positive and experienced an overall increase, indicating that tax liabilities were not aligned with operating performance.
- Net Operating Profit Before Taxes (NOPBT)
- Operating profitability remained negative across all reported years, characterized by significant volatility. After a period of relatively stable losses in 2018 and 2019, a sharp contraction in losses occurred in 2020. However, this was followed by a substantial expansion of losses in 2021 and 2022, culminating in a peak loss of $455.785 million in the final year of the period.
- Cash Operating Taxes
- A consistent upward trend in cash tax payments was observed from 2018 through 2021, with values rising from $102 thousand to $5.911 million. A reversal occurred in 2022, where cash taxes decreased to $4.236 million. The payment of cash taxes despite continuous operating losses suggests the presence of taxable income from non-operating sources or the impact of non-deductible expenses.
- Effective Cash Tax Rate (CTR) Dynamics
- The effective cash tax rate reflects a mathematical inverse relationship due to the combination of positive cash tax outflows and negative NOPBT. The relative impact of taxes peaked in 2020 when the operating loss was at its lowest point ($29.256 million) while tax payments continued to rise. By 2022, the drastic increase in operating losses effectively diluted the cash tax rate, as the magnitude of the loss grew at a significantly faster pace than the tax obligations.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?